The title N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)formamide derivative is obtained by covalently linking T or Q and T with N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)formamide fragment, and has structural formulas as shown in claim 1, wherein Q is linking group, and is linear or branched alkylene chain composed of 1-10 CH₂ or CH, and the linear or branched alkylene chain is linked with T via -NH-; and T is any one of fragments having structural formulas as shown in claim 1. The derivative has a specific structural formula as shown in claim 2, and is 2-(2,6-dioxopiperidin-3-yl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-1,3-dioxoisoindoline-5-carboxamide. The derivative can effectively inhibit activity of human chronic myeloid leukemia cells and human gastrointestinal stromal tumor cells, and can be used in the preparation of drugs for treatment and/or prevention of hyperproliferative diseases, in particular for treatment of chronic myeloid leukemia and gastrointestinal stromal tumor.